Foghorn management will review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including new preclinical combination data being presented at the 2025 AACR Annual Meeting. In addition, the company will share new preclinical data from their Selective CBP degrader and Selective EP300 degrader programs and provide an overview of their Selective ARID1B degrader program. The details of Foghorn's upcoming oral and poster presentations at AACR 2025 can be found here. Investor Event Info ...